Structure-based virtual screening and biological evaluation of potent and selective ADAM12 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 24, 2004, Pages 6071-6074

  Oh, Myungsok ^a   Im, Isak ^a   Lee, Yong Jae ^a   Kim, Young Hoon ^b   Yoon, Jeong Hyeok ^b   Park, Hye Gyeong ^c   Higashiyama, Shigeki ^d   Kim, Yong Chul ^a   Park, Woo Jin ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b IDRTech Inc   (South Korea)

^c Pusan National University   (South Korea)

^d EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ADAM12; Inhibitors; Virtual screening

Indexed keywords

A DISINTEGRIN AND METALLOPROTEASE; A DISINTEGRIN AND METALLOPROTEASE 12 INHIBITOR; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER MODEL; DATA BASE; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; MOLECULAR MODEL;

ADAM PROTEINS; COMPUTER-AIDED DESIGN; DRUG EVALUATION, PRECLINICAL; MEMBRANE PROTEINS; METALLOENDOPEPTIDASES; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 8844224202     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.09.082     Document Type: Article

References (18)

1. Y. Cao, Z. Zhao, J. Gruszczynska-Biegala, and A. Zolkiewska Mol. Cell Biol. 19 2003 6725
2. Z. Zhao, J. Gruszczynska-Biegala, T. Cheuvront, H. Yi, H. von der Mark, K. von der Mark, S.J. Kaufman, and A. Zolkiewska Exp. Cell Res. 298 2004 28
3. M.C. Schaub, M.A. Hefti, R.A. Zuellig, and I. Morano Cardiovasc. Res. 37 1998 381
4. P. Elliott, and W.J. McKenna Lancet 363 9424 2004 1881
5. M. Asakura, M. Kitakaze, S. Takashima, Y. Liao, F. Ishikura, T. Yoshinaka, H. Ohmoto, K. Node, K. Yoshino, H. Ishiguro, H. Asanuma, S. Sanada, Y. Matsumura, H. Takeda, S. Beppu, M. Tada, M. Hori, and S. Higashiyama Nat. Med. 8 2002 35
6. S. Tokumaru, S. Higashiyama, T. Endo, T. Nakagawa, J.I. Miyagawa, K. Yamamori, Y. Hanakawa, H. Ohmoto, K. Yoshino, Y. Shirakata, Y. Matsuzawa, K. Hashimoto, and N. Taniguchi J. Cell Biol. 151 2000 209
7. F.G. Spinale, M.L. Coker, S.R. Krombach, R. Mukherjee, H. Hallak, W.V. Houck, M.J. Clair, S.B. Kribbs, L.L. Johnson, J.T. Peterson, and M.R. Zile Circ. Res. 85 1999 364
8. N. Ito, S. Nomura, A. Iwase, T. Ito, F. Kikkawa, M. Tsujimoto, S. Ishiura, and S. Mizutani Biochem. Biophys. Res. Commun. 314 2004 1008
9. INSIGHT2000; Accelrys, Inc.: San Diego, CA
10. http://www.idrtech.com
11. S. Grüneberg, M. Stubbs, and G. Klebe J. Med. Chem. 45 2002 3588
12. M. Oh, S.Y. Kim, Y.S. Oh, D.Y. Choi, H.J. Sin, I.M. Jung, and W.J. Park Anal. Biochem. 323 2003 7
13. Generation of pHS/GMII-AP was described elsewhere. A DNA fragment encoding ADAM12 cleavage site (amino acids 84-162 of HB-EGF) was amplified, and inserted into the HindIII/NheI site of pHS/GMII-AP, resulting in pHS/GMII-HB-EGF-AP. The full-length ADAM12 and catalytic site deletion mutant ADAM12 (Δ205 → 413) coding sequences were amplified and inserted into the XhoI/BamHI site of pMK33/pMtHygor, resulting in pMT/wtADAM12 and pMT/Δ mutant ADAM12, respectively. Therefore, the substrate and protease constructs are under the control of Drosophila hsp70 and metallothionein promoters, respectively
14. The compounds were purchased from ChemBridge, Inc. (San Diego, CA)
15. 2, 0.005% Brij 35, pH 9.0) for 4 h at 37°C. The cleavage of the substrate was measured with a fluorometer (Molecular Devices) at excitation and emission wavelengths of 320 nm and 405 nm, respectively. Dose-dependent inhibition of ADAM12 was analyzed using SigmaPlot (SPPS Inc.)
16. H.A. Carlson, and J.A. Cammon Mol. Pharmacol. 57 2000 213
17. http://www.accelrys.com/doc/life/insight2000.3L
18. K. Maskos, C. Fernandez-Catalan, R. Huber, G.P. Bourenkov, H. Bartunik, G.A. Ellestad, P. Reddy, M.F. Wolfson, C.T. Rauch, B.J. Castner, R. Davis, H.R. Clarke, M. Petersen, J.N. Fitzner, D.P. Cerretti, C.J. March, R.J. Paxton, R.A. Black, and W. Bode Proc. Natl. Acad. Sci. USA 95 1998 3408